Document:

exv10w43

 

Exhibit 10.43

Confidential Materials omitted and filed separately with the Securities
and Exchange Commission. Asterisks denote omissions.

[ENGLISH TRANSLATION]

AGREEMENT

between

The Free State of Bavaria, represented by the ministry of environment, health and consumer
protection (StMUGV), Rosenkavalierplatz 2, 81925 Munich

(hereinafter referred to as “StMUGV”)

and

VIVACS GmbH, Am Klopferspitz 19, 82152 Martinsried, Germany, represented by its managing director,
Mr. Karl Heller

(hereinafter referred to as “VIVACS”)

Preamble

	1.a)	 	 The StMUGV intends and is obliged to strengthen Bavaria as development and research location.
Thus the StMUGV is particularly interested in encouraging and supporting young innovative
enterprises in the region.
	 
	   b)	 	The Free State of Bavaria owns a pre-vaccine for small pox that was approved between 1977
and 1987. The pre-vaccine contains the Modified Vacciniavirus Ankara (MVA) as active live
vaccine. The Bavarian institute for vaccination had developed this vaccine and had
documented its preparation.
	 
	2.a)	 	 VIVACS is a biotech company, located in the Gründerzentrum IZB (Founders’ Center) in Munich
that specializes in the development and production of viral vectors and recombinant viral
vectors that may be used as vaccines against infectious diseases or cancer.
	 
	   b)	 	VIVACS works primarily with MVA as vector system. The employees of VIVACS are all
experienced with the treatment, the breeding, the reproduction and the preparation of
recombinants from MVA and from other orto pox viruses.
	 
	   c)	 	It is VIVACS’ declared goal to harmonize the standards in the field of Vaccinavirus
technology and to make the promising MVA technology available to a broad scientific and
industrial community.
	 
	   d)	 	Based on this goal VIVACS considers itself a service provider that not only develops
recombinant virus vectors by order of third parties but wishes to produce and offer
standardized reference material, for example control vectors.
	 
	   e)	 	In order to reach the goals described under d) VIVACS prefers to work with standardized
and well-documented starting materials (Ausgangsmaterialien) and executes all works
according to a standard similar to GLP. Within medium term VIVACS aims for a GLP
certification.

 

 

	   f)	 	VIVACS is interested in using and marketing the pre-vaccine owned by StMUGV as starting
material (Ausgangsmaterial) for the production of standardized control vectors, reference
materials and for the production of recombinant virus vectors.
	 
	3.	 	In order to realize their respective goals and in accordance with the following definitions
the parties agree as follows:

1. Definitions

“Documentation” means the documentation of the Material’s development and all available documents
regarding the clinical application that contain details on the term of application, the number of
patients, the form of application, the compatibility etc. of the Material.

“Development Product” (Entwicklungsprodukt) means an MVA-Starting Material (MVA-Ausgangsmaterial)
that has been genetically modified according to the requirements of a customer and that is only
released for scientific purposes. Development Products are, for example, recombinant MVA-virus
vectors that express a reference gene under a regulatory control region.

“Material” means small pox pre-vaccine, MVA strain according to schedule 1.

“MVA Starting Material” (MVA-Ausgangsmaterial) means a characteristic Isolate that was
“plaque-isolated” from the Material. This isolate is then depurated, reproduced and tested as
Master Seed Virus under GMP conditions. It constitutes the starting material (Ausgangsmaterial) for
any of VIVACS’ further activities.

“License Fee” means the income generated by sales and license agreements regarding the application
and use of the Products.

“Net revenue” means the amount invoiced for the Products without legal taxes and freight or
packaging surcharges.

“Reference Material” means a suspension with a precisely defined concentration of MVA Starting
Material or Development Product that helps customers to define the virus concentration in a test
dilution and that is exclusively released for scientific purposes.

“Products” are viruses or viral products that are won by using the handed over Material
(überlassenes Material) including but not limited to Development Products, Reference Materials and
Reproduction Products or new developments from the handed over Material.

“Property Right” means all documented suggestions for improvements and applications for inventions
and patents, utility models and know-how.

“Reproduction Product” means the MVA-Starting Material that is reproduced under standardized
conditions.

2. Rights and Duties of StMUGV

	1.	 	StMUGV makes available to VIVACS Material according to Schedule 1 to be used as Starting
Material for the production of recombinant virus vectors for research purposes and for the
development of vaccines. In addition StMUGV hands over to VIVACS a copy of the relevant
documentation and all existing information on clinical vaccination trials that were conducted
with the small pox pre-vaccine.

 

 

	2.	 	StMUGV permits VIVACS to win an isolate from the provided Materials that may be then used and
marketed as MVA Starting Material for further Products.
	 
	3.	 	StMUGV undertakes to inform VIVACS in case MVA Starting Material is made available to a third
party under generally similar but better conditions than the conditions agreed on under
Section 3.6.1 of this agreement in connection with schedule 2 and agrees to amend Section
3.6.1 of this agreement in connection with schedule 2 based on such better conditions.

3. Rights and Duties of VIVACS

	1.	 	VIVACS does use the provided Materials and the Documentation exclusively for the development
of standardized Reference Materials, control vectors and for the production of recombinant
virus vectors in Bavaria.
	 
	2.	 	VIVACS undertakes not to give the provided Materials in their starting form (überlassene
Materialien in ihrer Ausgangsform) to third parties and to secure them against being taken
away by third parties.
	 
	3.	 	Any remaining Materials in their starting form must be returned to StMUGV in case VIVACS is
liquidated and in case of termination of this agreement.
	 
	4.	 	VIVACS is the sole producer of the Products.
	 
	5.	 	VIVACS is the owner of the Products and is entitled to market or license them worldwide.
	 
	6.1	 	VIVACS undertakes to allow StMUGV a share in the marketing of the Products according to the
breakdown in Schedule 2. Such share is to be paid in Euro.
	 
	6.2	 	VIVACS undertakes to transfer the due payments once a year and with effect of September 1 of
each year respectively to the account of the “Staatsoberkasse Bayern, Buchungsstelle München”,
account no. 24592 at the Bayer.Landesbank München, bank identification code 700 500 00.
	 
	6.3	 	VIVACS undertakes to forward StMUGV a report on its marketing activities, the marketing
success that have been achieved according to Schedule 2 and the payments due to StMUGV by
August 31, of each year respectively.
	 
	7.1	 	VIVACS undertakes to keep the most precise account on the development, the production and the
marketing of Products that are based on the provided Materials. Such books must be retained
for at least 10 years.
	 
	7.2	 	VIVACS undertakes to allow inspection of the books named in Section 7.1 during normal
business hours and in VIVACS’ premises upon request of StMUGV or an independent auditor or
other expert named by StMUGV. StMUGV shall bear the costs of such audit.
	 
	7.3	 	In case the audit reveals that the paid sum deviates from the sum payable to StMUGV by more
than EUR 1,000, VIVACS shall bear the costs of the audit.
	 
	8.	 	VIVACS may use the Material’s history for own marketing purposes.

 

 

4. Further/New Developments, Trademark Rights

	1.	 	To the extent that new inventions are made in the course of VIVACS’ development and
production of Products, VIVACS is solely entitled to apply for patents and to effect Trademark
Rights.
	 
	2.	 	VIVACS shall bear all costs for the application and enforcement of Property Rights.

5. Exclusion of Warranty and Liability

	1.	 	StMUGV does not warrant and is not liable for the quality and the security profile for the
handed over Materials.
	 
	2.	 	StMUGV does not warrant and is not liable for the applicability of the handed over Materials
for the contractual purposes, in particular that the handed over Materials are viable and
augmentable.
	 
	3.	 	StMUGV does not warrant and is not liable for the completeness and correctness of the handed
over documentation.
	 
	4.	 	StMUGV is furthermore not liable for any damages whatsoever that may arise from the handed
over Materials, particularly from the contact and the use of the handed over Materials.
	 
	5.	 	VIVACS undertakes to indemnify StMUGV or its employees from all claims for damages of third
parties that may arise from the use or marketing of Products from the originally handed over
Materials.
	 
	6.	 	VIVACS further undertakes to effect relevant liability insurances and to exclude any claims
for damages of third parties in all marketing or licensing agreements with third parties.

6. Other

	1.	 	VIVACS may assign this agreement and possible Property Rights including all rights and
obligations to a legal successor/assignee or contribute it to a trading company or other legal
entity only upon StMUGV’s consent.
	 
	2.1	 	VIVACS undertakes to pay a contractual penalty of up to EUR 50,000 in case it breaches the
obligations provided for in Sections:

- 3.2

- 3.3

- 3.6.1

- 3.7.1

- 3.7.2

	2.2	 	StMUGV is entitled to define the actual amount of the contractual penalty within the given
frame of EUR 50,000 in each case.

 

 

	2.3	 	In case VIVACS does not fulfill a contractual obligation at all or not in a proper manner,
the contractual penalty becomes due if VIVACS is in breach according to the provisions of the
German Civil Code (BGB). In case of a default the penalty becomes due with the default.
	 
	2.4	 	StMUGV reserves the right to claim further damages. In case StMUGV claims damages in addition
to the contractual penalty, the forfeited contractual penalty shall be credited against the
claim for damage.

7. Termination

	1.	 	Any party is entitled to terminate the agreement for cause without a notice period. Cause for
termination is given if the other party has willfully breached one of its contractual
obligations and such breach is not cured within a reasonable time limit, set by the other
party.
	 
	2.	 	Cause for a termination by StMUGV is given, in case of VIVACS’ repeated default of payment or
if VIVACS becomes insolvent or is liquidated.
	 
	3.	 	Any rights and obligations related to marketing agreements that have at the time of the
termination already been entered into by VIVACS shall not be affected by the termination. New
marketing agreements may not be entered into.

8. Miscellaneous

	1.	 	This agreement is subject to German law.
	 
	2.	 	The relevant court of Jurisdiction for any possible disputes shall be the Munich County Court
I (Landgericht München I).
	 
	3.	 	There are no side agreements. Any amendments to this agreement shall only be valid if they
are made in written form and executed by the parties.
	 
	4.	 	In case any of the provisions of this agreement is or becomes void or in case the agreement
is unintentionally silent, the other provisions shall not be affected. Instead of the void
provision a valid provision that comes closest to the parties intention shall be deemed agreed
on. The same applies in case the agreement is unintentionally silent.

Signatures/June 16, 2005

 

 

Schedule 1

Specifications of the “Material”

The Material was produced in accordance with

-   Guideline on general requirements for the
production and trial of sera, vaccines and test –
antigens (German Federal Gazette vol. 27, No. 206
dated November 5, 1975)

-   Guideline on special requirements for the
production and trial of Vaccinia virus vaccines
for the pre-vaccination at the small pox first
vaccination (German Federal Gazette vol. 29, No.
138 dated July 28, 1977)

	 	 	 	 	 
	MVA pre-vaccine:

	 	 approval
	 	January 31, 1977
	 
	 	 	 	 
	 

	 	approval expired
	 	December 31, 1987 

	 	 	 	 	 
	Handed over to VIVACS:	 	Charge MVA 470 MG
	 
	 	 	 	 
	 	 	(Including the copies of the production documentation of
 MVA 470 MG and the seed virus
MVA 460 MG)
	 
	 	 	 	 
	 

	 	Release of Charge: 
	 	December 12, 1977 
	 
	 	 	 	 
	 

	 	Amount: 
	 	5 containers of 0.5 ml each 
	 
	 	 	 	 
	 

	 	 	 	(before Lyophilisation)

The Material is not intended for consumers. The Material, which was developed by the Bavarian
institute for vaccination and is currently stored for research purposes by the State Office for
Health and security of food may exclusively be used for research purposes.

 

 

Schedule 2

In accordance with the agreement under Section 3.6, VIVACS undertakes to allow StMUGV shares in the
profits pursuant to the following itemization:

	1.	 	From the marketing of Products that are given away for research purposes, the StMUGV
receives:

- [**] % of the net revenue during the first year

- [**] % of the net revenue during the second year

- [**] % of the net revenue during the third, fourth and fifth year

- [**] % of the net revenue during any further year

	2.	 	From the marketing of Products that are given away or licensed for other purposes,
particularly for medical and diagnostic use, the StMUGV receives:

- [**] % of the net revenue or the License Fees

	3.	 	From the marketing of Products that are licensed as Starting Material for the production of a
small pox vaccine, the StMUGV receives:

- [**] % of the License Fees

 

 

Schedule 3

Declaration on ownership

The Free State of Bavaria owns a pre-vaccine against small pox that was admitted between 1977 and
1987.

This vaccine contains the Modified Vacciniavirus Ankara (MVA) as active live vaccine. This vaccine
had been produced and its production documented by the Bavarian institute for vaccination.

Vivacs GmbH received according to the agreement dated June 16, 2005 5 containers containing 0.5 ml
of this vaccine (Charge MVA 470 MG)

Signature/June 14, 2005exv10w1

 

Exhibit 10.1

Assignment and Assumption Agreement

     THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (the “Agreement”) is made as of October 19,
2006, between Republic WPB LLC (“Republic”) and the West Palm Beach Community Redevelopment Agency,
acting for itself and on behalf of the City of West Palm Beach (together, “CRA”).

     WHEREAS,
Republic and CRA are parties to that certain Professional Services Agreement for
the City Center Project (RFP No. 08/04-109), dated as of October 26, 2004, as amended by Amendment
No. 1 thereto, dated as of March 28, 2005 and by Amendment No. 2 thereto, dated as of March 13,
2006 (collectively, the “Professional Services Agreement”);

     WHEREAS, Republic represents that funds previously received by Republic from CRA were used
solely to pay subcontractor expenses or for purposes of partial reimbursement of Republic’s out of
pocket expenses;

     WHEREAS,
upon the terms and subject to the conditions specified herein and as of the date hereof, Republic has agreed to contribute, assign, transfer and convey to CRA all
of its right, title and interests in the Professional Services Agreement; and

     WHEREAS, capitalized terms used herein and not otherwise defined shall have the meanings specified
in the Professional Services Agreement.

     NOW, THEREFORE, in consideration of the premises and for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, Republic and CRA hereby covenant and
agree as follows:

     1. Assignment and Assumption. Upon the terms and subject to the conditions specified
herein and as of the date hereof, Republic hereby contributes, assigns, transfers and conveys all
of its rights under the Professional Services Agreement and CRA hereby accepts all of such rights
and assumes all of Republic’s obligations and liabilities under the Professional Services
Agreement.

     2. Third Party Obligations; Payment to Republic, Without limiting the foregoing, CRA hereby
assumes and agrees to pay, honor, discharge and perform, as the case may be, in a timely manner and
in accordance with their respective terms, all of the liabilities and obligations of Republic to
Catalfumo Construction & Development, Song and Associates,
Ardaman & Associates, and/or Cushing
Demolition with respect to the Professional Services Agreement, including but not limited to all
responsibility for amounts incurred to date, or to be incurred in the
future. The foregoing
includes full responsibility for payment by CRA in full of all amounts set forth in Republic’s
requisition dated as May 17, 2006 with respect

1

 

to Catalfumo Construction & Development, Song and Associates, Ardaman & Associates, and/or
Cushing Demolition. CRA agrees to indemnify and otherwise hold Republic harmless as to any and all
obligations as to Catalfumo Construction & Development, Song and Associates, Ardaman & Associates,
and/or Cushing Demolition.

     3. Release. Republic hereby expressly and unconditionally releases CRA and the City of West
Palm Beach, as well as CRA’s successors, predecessors, departments, affiliates, agents, directors
(in both their individual and corporate capacities), officers (in both their individual and
corporate capacities), employees, Commissioners (in both their individual and governmental
capacities), attorneys, insurers, and assigns, both past and present,
from any and all claims,
demands, suits, or causes of actions, of any kind or nature whatsoever, whether in law or in
equity, and including but not limited to those arising out of or related to the City Center Project
and/or the Professional Services Agreement. CRA and the City of West Palm Beach hereby expressly
and unconditionally release Republic, as well as Republic’s parents (including, without limitation,
Republic Property Trust, Republic Property Limited Partnership and Republic Property TRS, LLC),
subsidiaries, successors, predecessors, departments, affiliates, agents, directors (in both their
individual and corporate capacities), officers (in both their individual and corporate capacities),
employees, attorneys, insurers, and assigns, both past and present, from any and all claims,
demands, suits, or causes of actions, of any kind or nature whatsoever, whether in law or in
equity, and including but not limited to those arising out of or related to the City Center Project
and/or the Professional Services Agreement. This Agreement shall constitute, and in executing this
Agreement Republic and CRA hereby enter into, a full release as to any and all claims, including
cross-claims or third party claims, relating to any and all matters between them, including but not
limited to any claims involving the City Center Project and/or the Professional Services Agreement,
and it is the intent of Republic and CRA to fully, finally, and forever settle and release all
claims between them, which do now exist, may exist or may heretofore have existed between them. In
furtherance of such intention, the releases given herein shall be and shall remain in effect as
full and complete releases of all such matters notwithstanding the discovery or existence of any
additional or different claims or facts related thereto. In addition, Republic agrees to execute
mutual releases between Republic and each of Catalfumo Construction & Development, Song and
Associates, Ardaman & Associates, and Cushing Demolition, subject to agreement to same on the part
of each of Catalfumo Construction & Development, Song and Associates, Ardaman & Associates, and
Cushing Demolition.

2

 

     4. Effect of Assignment. This Agreement and the covenants and agreements herein set forth
shall inure to the benefit of the parties hereto and their respective successors and assigns and
shall be binding upon the parties hereto and their respective successors and assigns.

     5. Governing Law. The validity, interpretation and effect of this Agreement shall, to the
extent the particular subject matter is controlled by state law, be governed by and be construed in
accordance with the laws of the State of Florida, without giving effect to the conflicts of laws
provisions thereof.

     6. Counterparts. This Agreement may be executed in one or more counterparts, each of which
may be executed by one or more of the parties hereto, with the same force and effect as through all
parties who executed such counterparts had executed but one instrument.

     7. Amendment; Waiver. Any amendment hereto shall be effective only if signed by all parties
hereto. No waiver of any provisions of this Agreement shall be valid unless in writing and signed
by the party against whom enforcement is sought.

[Signature Page Follows]

3

 

     IN WITNESS WHEREOF, each of the undersigned has caused this Agreement to be duly executed and
delivered is its name and on its behalf as of the date first written above.

	 	 	 	 	 	 	 
	 	 	REPUBLIC WPB LLC	 	 
	 
	 	 	 	 	 	 
	 

	 	By :
	 	/s/ Gary Siegel
 

	 	 
	 	 	Name: Gary R. Siegel	 	 
	 	 	Title : Chief Operating Officer	 	 
	 
	 	 	 	 	 	 
	 	 	WEST PALM BEACH COMMUNITY

REDEVELOPMENT AGENCY	 	 
	 
	 	 	 	 	 	 
	 

	 	By :
	 	/s/ Lois Frankel
 

	 	 
	 	 	Name : 	 	 
	 	 	Title :	 	 
	 
	 	 	 	 	 	 
	 	 	CRA ATTORNEY
	 	 
	 	 	Approved As To Form
	 	 
	 	 	And Legal Sufficiency
	 	 
	 
	 	 	 	 	 	 
	 

	 	By :
	 	/s/ [ILLEGIBLE]
 

	 	 
	 	 	Date : 10-12-06	 	 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]